Your browser is no longer supported. Please, upgrade your browser.
Brickell Biotech, Inc.
Index- P/E- EPS (ttm)-2.41 Insider Own0.80% Shs Outstand53.52M Perf Week8.04%
Market Cap64.80M Forward P/E- EPS next Y-0.49 Insider Trans13.97% Shs Float51.98M Perf Month75.46%
Income-24.40M PEG- EPS next Q-0.09 Inst Own10.70% Short Float4.28% Perf Quarter47.01%
Sales2.50M P/S25.92 EPS this Y13.60% Inst Trans8.03% Short Ratio0.67 Perf Half Y27.37%
Book/sh0.67 P/B1.81 EPS next Y31.00% ROA-114.80% Target Price- Perf Year-22.93%
Cash/sh0.38 P/C3.21 EPS next 5Y- ROE-187.40% 52W Range0.47 - 3.98 Perf YTD55.03%
Dividend- P/FCF- EPS past 5Y19.10% ROI-291.40% 52W High-69.60% Beta0.27
Dividend %- Quick Ratio3.50 Sales past 5Y-12.30% Gross Margin- 52W Low159.66% ATR0.11
Employees15 Current Ratio3.50 Sales Q/Q-91.70% Oper. Margin- RSI (14)71.35 Volatility8.57% 12.76%
OptionableNo Debt/Eq0.03 EPS Q/Q90.70% Profit Margin- Rel Volume0.99 Prev Close1.13
ShortableYes LT Debt/Eq0.01 EarningsNov 12 AMC Payout- Avg Volume3.33M Price1.21
Recom1.50 SMA2025.29% SMA5058.13% SMA20030.80% Volume3,302,173 Change7.08%
Aug-28-20Initiated Lake Street Buy $6
Aug-25-20Initiated Oppenheimer Outperform $5
Jan-19-21 07:00AM  
Jan-06-21 12:50AM  
Dec-07-20 07:30AM  
Nov-18-20 07:00AM  
Nov-16-20 08:00AM  
Nov-12-20 04:01PM  
Oct-29-20 08:00AM  
Oct-22-20 08:00PM  
Sep-29-20 10:30AM  
Sep-25-20 07:00AM  
Sep-10-20 04:05PM  
Sep-08-20 07:30AM  
Aug-31-20 04:05PM  
Aug-12-20 04:01PM  
Aug-03-20 04:05PM  
Jun-17-20 10:00PM  
Jun-15-20 06:30AM  
May-31-20 08:04AM  
May-13-20 04:01PM  
May-04-20 04:05PM  
Mar-18-20 04:01PM  
Mar-09-20 04:05PM  
Mar-04-20 06:30AM  
Feb-20-20 11:43AM  
Feb-18-20 06:30AM  
Jan-10-20 04:05PM  
Nov-13-19 04:05PM  
Oct-30-19 04:42PM  
Sep-03-19 06:45AM  
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McAvoy David R.General Counsel and CCOSep 18Buy0.846,0005,0396,000Sep 21 04:19 PM
McAvoy David R.General Counsel and CCOSep 18Buy0.8316,52613,71375,883Sep 21 04:19 PM
VERU DENNISON TDirectorSep 16Buy0.8014,64511,75850,810Sep 17 05:07 PM
VERU DENNISON TDirectorSep 15Buy0.8115,35512,41636,165Sep 17 05:07 PM